Equillium Inc
NASDAQ:EQ
Equillium Inc
Capital Expenditures
Equillium Inc
Capital Expenditures Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Capital Expenditures | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Equillium Inc
NASDAQ:EQ
|
Capital Expenditures
-$70k
|
CAGR 3-Years
37%
|
CAGR 5-Years
3%
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
Capital Expenditures
-$1B
|
CAGR 3-Years
-10%
|
CAGR 5-Years
-12%
|
CAGR 10-Years
-5%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Capital Expenditures
-$757m
|
CAGR 3-Years
-5%
|
CAGR 5-Years
0%
|
CAGR 10-Years
-4%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Capital Expenditures
-$1.3B
|
CAGR 3-Years
-12%
|
CAGR 5-Years
-15%
|
CAGR 10-Years
-3%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Capital Expenditures
-$277.7m
|
CAGR 3-Years
-7%
|
CAGR 5-Years
-29%
|
CAGR 10-Years
-20%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Capital Expenditures
-$991.3m
|
CAGR 3-Years
-20%
|
CAGR 5-Years
-14%
|
CAGR 10-Years
-10%
|
|
Equillium Inc
Glance View
Equillium, Inc. engages in the development of products for severe autoimmune and inflammatory, or immuno-inflammatory, disorders with high unmet medical need. The company is headquartered in La Jolla, California and currently employs 45 full-time employees. The company went IPO on 2018-10-12. The firm develops products to treat severe autoimmune and inflammatory disorders with unmet medical needs. The firm's initial product candidate, itolizumab (EQ001), is a clinical-stage, monoclonal antibody that selectively targets CD6, a co-stimulatory receptor differentially expressed on subsets of pro-inflammatory T cells. The firm's CD6 plays a central role in the modulation of effector T cell, or Teff cell, activity and trafficking. Activated Teff cells drive several immuno-inflammatory diseases across therapeutic areas including transplant science, systemic autoimmunity, pulmonary, neurologic, gastrointestinal, renal, vascular, ophthalmic and dermatologic disorders. The company also provides structured-domain peptides, including BNZ-1 and BNZ-2, entirely in-house from product discovery platform. These lead product candidates are multi-specific inhibitors that targets range of immuno-inflammatory indication.
See Also
What is Equillium Inc's Capital Expenditures?
Capital Expenditures
-70k
USD
Based on the financial report for Mar 31, 2025, Equillium Inc's Capital Expenditures amounts to -70k USD.
What is Equillium Inc's Capital Expenditures growth rate?
Capital Expenditures CAGR 5Y
3%
Over the last year, the Capital Expenditures growth was -1%. The average annual Capital Expenditures growth rates for Equillium Inc have been 37% over the past three years , 3% over the past five years .
You don't have any saved screeners yet